P6620
P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2009272-81-3
- Fòrmula: C19H18N2O2
- Peso molecular:306.36
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
USP7 |
P6620 (0-2.0 μM; 72 h) potently inhibits the viability of MHCC97H and HepG2 human hepatocellular carcinoma cells with an IC50 of 11.31 μM, and 10 μM or 20 μM P6620 significantly reduces cell viability after 72 h of incubation[1].
P6620 (5-20 μM; 48 h) dose-dependently decreases USP7 and LRRC41 protein levels in MHCC97H and HepG2 human hepatocellular carcinoma cells after 48 h of incubation, and MG132 reverses the P6620-induced reduction in LRRC41 protein[1].
P6620 (10-20 μM; 48 h) significantly inhibits the invasion and migration of MHCC97H and HepG2 human hepatocellular carcinoma cells after 48 h of incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma MHCC97H, HepG2 cells
-
Concentration:0-2.0 μM (viability measurement); 10, 20 μM (24-72 h incubation)
-
Incubation Time:24-72 h (10, 20 μM treatment)
-
Result:Reduced HCC cell viability in a concentration-dependent manner, with an IC50 of 11.31 μM.
Significantly decreased the viability of MHCC97H and HepG2 cells compared with untreated controls when treated with 10 μM or 20 μM.
-
Cell Line:human hepatocellular carcinoma MHCC97H, HepG2 cells
-
Concentration:5-20 μM (48 h incubation); 10 μM (48 h incubation, followed by 8 h incubation with 10 μM MG132)
-
Incubation Time:48 h (5-20 μM treatment); 48 h + 8 h (10 μM P6620 + 10 μM MG132 treatment)
-
Result:Dose-dependently reduced USP7 and LRRC41 protein levels in MHCC97H and HepG2 cells when treated with 5, 10, or 20 μM for 48 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude mice (male, 4 weeks old, subcutaneously inoculated with MHCC97H cells)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; 5 times weekly; 14 days
-
Result:Significantly reduced tumour weight compared with the control group.
Significantly reduced Ki67 and USP7 expression in tumour tissues relative to controls.
Chemical Information
-
No. CAS 2009272-81-3
-
Peso molecular 306.36
-
Fòrmula C19H18N2O2
-
SMILES
OC1=CC=C(C2=C(CC)C(C3=CC=C(O)C=C3)=C(N)N=C2)C=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
P6620 Related Classifications
HY-183078 Related Classifications
Powered by Bioz